Christof Vulsteke discusses KEYNOTE-905 results with Ashish Kamat. The phase 3 trial enrolled cisplatin-ineligible muscle-invasive bladder cancer patients, median age 73, receiving perioperative ...
Oliver Sartor: Hi, I'm Oliver Sartor with Uro Today, covering metastatic castration resistant prostate cancer at ASCO 2025. A real delight for me to welcome Mark Stein, associate professor at Columbia ...
Zachary Klaassen hosts Luis Salgado to discuss metastasis-directed therapy for low-volume hormone-sensitive prostate cancer. The conversation highlights the challenge of interpreting disease volume in ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Laser technology has rapidly propelled surgical techniques in urinary tract calculus removal. The thulium fiber laser (TFL) is a relatively new tool that can be used for laser lithotripsy, as an ...
Read the Full Video Transcript Andrea Miyahira: Hi, everyone. I'm Andrea Miyahira with the Prostate Cancer Foundation. Thank you for joining me for a special Women in Science episode. And joining me ...
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman discusses his team's work with Terbium-161 in the VIOLET clinical trial at Peter Mac. He explains Terbium-161 offers both beta and Auger electron ...
At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...
At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber discusses lutetium PSMA therapy beyond six standard cycles. He distinguishes between extended treatment (continuous administration) and ...
AI Applications for Simplifying Radiopharmaceutical Dosimetry Workflows "Presentation" - Irène Buvat
At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...
At the 2025 UCSF-UCLA PSMA Conference, Jeremie Calais provides an overview of ongoing PSMA radiopharmaceutical therapy trials across different disease stages. He reviews major phase 3 trials in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback